Tryp Therapeutics retains IMS investor relations
KELOWNA, British Columbia, Sept. 13, 2022 (GLOBE NEWSWIRE) — Therapeutic TrypInc. (CSE: TRYP) (OTCQB: TRYPF) (“try“or the”Company“), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced it will continue IMS Investor Relations (“SMI”) effective August 15, 2022. IMS will provide capital markets advice, corporate communications and strategic investor outreach.
Jim Gilligan, Chief Executive Officer of Tryp Therapeutics, said: “We have made tremendous progress in advancing our drug development strategy focused on attractive under-treated indications such as eating disorders and pain. chronic, and we expect to achieve several key strategic milestones during the second mid-2022 and into 2023. IMS Investor Relations is a reputable company, and we look forward to working with them to ensure that we communicate proactively and productive our progress on Wall Street.
John Nesbett, Founder and Chairman of IMS Investor Relations, said: “Tryp Therapeutics is at an exciting time in its development as it continues to progress through the clinical trial process and to file patents for its intellectual property. potentially revolutionary. We are thrilled to partner with a company with such an experienced and capable management team, a proven track record in biotechnology, a world-class scientific advisory board, and a potentially transformative product. We look forward to leveraging our expertise to convey the value of Tryp to investors. »
IMS will work closely with Tryp management to develop and deploy a strategic capital markets program. Initiatives should include, but not be limited to: refining overall corporate and investment messaging, ongoing strategic advice, and arranging presentations to investors and analysts in the financial community.
About IMS Investor Relations
IMS Investor Relations (www.imsinvestorrelations.com) helps small and medium-sized public companies ensure that their stock market listing is a vital strategic asset with a credible and resonant brand, aligned shareholders and a valuation that reflects the long-term value of the business. IMS was founded to shine a light on micro-cap and mid-cap companies, a sector often misunderstood, under-followed and undervalued by Wall Street. The company’s extensive expertise in this area, its trusted reputation and extensive relationships with analysts, institutional investors, family offices and brokers open doors often closed to others. IMS prides itself on its longstanding client relationships due to its ability to understand its clients’ needs and its agility to meet the challenges of today’s ever-changing financial landscape. In consideration for the services provided, Tryp agreed to pay IMS an initial monthly fee of $8,000, which commenced August 15, 2022. Tryp’s engagement with IMS is on a monthly basis and may be terminated by either either party on 30 days written notice. IMS has no interest, direct or indirect, in the Company or its securities, and currently has no right or intention to acquire any such interest during the term of the engagement.
About Tryp Therapeutics
Tryp Therapeutics is a clinical-stage biotechnology company focused on the development of psilocybin-like molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-For-Neuropsychiatric Disorders (PFN™) program focuses on the development of synthetic molecules related to psilocybin as a new class of drugs for the treatment of binge eating, chronic pain and other directions. The company has begun enrolling patients in its Phase II trial for the treatment of binge eating at the University of Florida and recently announced an upcoming Phase IIa clinical trial with the University of Michigan to evaluate TRP- 8802 for fibromyalgia. TRP-8803 is a proprietary psilocybin product that uses a new formulation and route of administration to potentially improve efficacy, safety, and patient experience. For more information, please visit www.tryptherapeutics.com.
Certain information contained in this press release constitutes forward-looking information. In some, but not necessarily all, cases, forward-looking information may be identified by the use of forward-looking terminology such as “anticipates”, “target”, “expects” or “does not expect”. to”, “is planned”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of these words and phrases or state that certain actions, events or results “could”, “could”, “would”, “could”, “will” or “will be taken”, “will occur” or ” will be achieved”. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but rather represent the management’s expectations, estimates and projections regarding future events.
Forward-looking information is necessarily based on a number of opinions, assumptions and estimates which, although considered reasonable by Tryp as of the date of this press release, are subject to known and unknown risks, uncertainties , assumptions and other factors that may cause actual results, level of activity, performance or achievements to differ materially from those expressed or implied by such forward-looking information, including, but not limit, the factors described in more detail in the “Risk Factors” section of Tryp’s final prospectus available at www.sedar.com. These factors are not intended to represent a complete list of factors that could affect Tryp; however, these factors should be carefully considered. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this press release are made as of the date of this press release, and Tryp expressly disclaims any obligation to update or modify any statements containing forward-looking information, or the underlying factors or assumptions, that whether as a result of new information, future events or otherwise, except as required by law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATORY SERVICE PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE SUITABILITY OR ACCURACY OF THIS RELEASE.
John Nesbett/Jennifer Belodeau
IMS Investor Relations
51 Locust Avenue, New Canaan, Connecticut